Herlin Jones
Hepatocellular Carcinoma (HCC) is one of the most frequent cancers in the world, and its frequency is on the rise. This review examines the present and expanding amount of evidence on the use of immune checkpoint inhibitors in patients with advanced HCC who are awaiting liver transplantation, as well as many of the unanswered concerns. Immunotherapy clearly has a function in HCC, and more clinical trials will assist to define the indications and criteria for its usage. Hepatocellular Carcinoma (HCC) is the most frequent kind of liver cancer and the third greatest cause of mortality from cancer in the world. Liver-directed medications for locoregional control or down-staging prior to final surgical therapy with hepatic resection or liver transplantation have been extensively explored and are the pillars of current treatment recommendations for early and intermediate-stage illness. Our existing treatment approaches are insufficient to enhance disease-specific and overall survival as the prevalence of HCC has continued to rise, and more patients are presenting with advanced illness. Until recently, sorafenib was the only systemic treatment available, and it had a poor track record. Immuno-arrival oncology's has piqued curiosity, and it has shifted the treatment paradigm for HCC. Combination regimens such as atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and pembrolizumab with Lenvatinib have recently showed excellent responses of 25%-35%, which is much greater than single agent responses. In advanced-stage HCC patients, complete responses to checkpoint inhibitor treatment have been recorded.